ClinicalTrials.gg
CompletedNCT00833482Updated Oct 25, 2012Results posted

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

A Phase 1 interventional study of Voriconazole and Atazanavir in Human Immunodeficiency Virus Type 1 (HIV-1) and HIV Infections, sponsored by Bristol-Myers Squibb. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-25.

Primary conditionHIV InfectionsRegistry: Acquired Immunodeficiency SyndromeReclassifiedWhy we changed it
Registry
Acquired Immunodeficiency Syndrome — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The registry often attaches Acquired Immunodeficiency Syndrome to studies about something else, and this study's title and listed conditions do not name it.
  2. The study's listed conditions name HIV Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Bristol-Myers Squibb · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
185
Allocation
Non-randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 73 studies testing atazanavir in HIV Infections — none open to participants now, 1 under way, 1 of them phase 3. atazanavir · HIV Infections.

Enrollment
20th of 69
185 · median 55
Started
2009
with 8 others
Phase 1
16 of 73
none open now
Registered
55th of 73
by date
Lead sponsor
25 of 73
Bristol-Myers Squibb

Among the 73 studies testing atazanavir in HIV Infections, this one is the 20th largest by enrollment of the 69 interventional ones that give a count, is one of 9 that started in 2009, is one of 16 in phase 1, and was the 55th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

Browse HIV Infections studies →

Open to participants now

None of the 73 studies testing atazanavir in HIV Infections is open now. The open studies under HIV Infections, anywhere →

About atazanavir

atazanavir: first FDA approval 2003 (REYATAZ), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 73 studies testing atazanavir in HIV Infections as a file.
02

Study summary

This study assesses the effects of voriconazole, 200 mg, administered twice daily (BID), on the steady-state pharmacokinetics of atazanavir administered as atazanavir/ritonavir, 300/100 mg once daily (QD), in healthy participants with functional CYP2C19 alleles. The study also reviews the effects of atazanavir/ritonavir, 300/100 mg QD, on the pharmacokinetics of voriconazole, 200 mg, BID in healthy participants with functional CYP2C19 alleles.

03

Conditions studied

  • Human Immunodeficiency Virus Type 1 (HIV-1)
  • HIV Infections

Browse trials for

04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 246 are open to participants now.

This study's enrollment of 185 is above the median of 80 across 3,491 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Acquired Immunodeficiency Syndrome. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants as determined by no deviation from normal
  • (BMI) of 18 to 32 kg/m\^2, inclusive. BMI=weight(kg)/height (m)\^2
  • Women who are not of (WOCBP)(ie, who are or surgically sterile) and men, ages 18 to 45 years, inclusive

Exclusion criteria

Exclusion Criteria:

  • Sexually active fertile men not using effective if their partners are WOCBP
  • Proven or suspected acute hepatitis (within 12 months prior to the 1st dose)
  • Any significant acute or chronic medical illness
  • Any gastrointestinal surgery that could impact on the absorption of study drug
  • Smoking more than 5 cigarettes per day
  • History of any hemolytic disorders (including drug-induced hemolysis)
  • History of acute or chronic pancreatitis
  • History of hypochlorhydria or achlorhydria
  • Men and women weighing \<40 kg
  • Positive blood screen for antibody, surface antigen, or -1 or HIV-2 antibody
  • Patients with galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 1
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
185 participants (actual)

Study arms

  • Active comparator
    Voriconazole, 200 mg BID (EM)

    Drug: Voriconazole

  • Active comparator
    Atazanavir/Ritonavir, 300/100 QD (EM & PM)

    Drug: Atazanavir · Drug: Ritonavir

  • Active comparator
    Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)

    Drug: Voriconazole · Drug: Atazanavir · Drug: Ritonavir

  • Active comparator
    Voriconazole, 50 mg BID (PM)

    Drug: Voriconazole

  • Active comparator
    Atazanavir/ritonavir, 300/100mgQD+voriconazole, 50mgBID (PM)

    Drug: Voriconazole · Drug: Atazanavir · Drug: Ritonavir

Interventions

  • Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.

  • Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.

    Also known as: Reyataz, BMS-232632

  • Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.

07

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in Participants Who Are Extensive Metabolizers (EM)

    EM participants are those with functional CYP2C19 alleles.

    Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle

  2. Time to Maximum Concentration (Tmax) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

    EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

    Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle

  3. Area Under the Plasma Concentration-time Curve in 1 Dosing Interval [AUC(TAU)] of Atazanavir Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

    EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

    Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle

  4. Tmax of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants

    Tmax=time to maximum concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle

  5. Cmax and Cmin of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants

    Cmax=maximum observed plasma concentration; Cmin=minimum observed plasma concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle

  6. AUC(TAU)of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants

    AUC(TAU)=area under the plasma concentration-time curve in 1 dosing interval; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

    Time frame: Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle

Secondary outcomes

  1. Cmax and Cmin of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

    Cmax=maximum observed plasma concentration; Cmin=minimum observed plasma concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

    Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle

  2. Tmax of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

    Tmax=time to maximum concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

    Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle

  3. AUC(TAU) of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

    AUC(TAU)=area under the plasma concentration-time curve in 1 dosing interval; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

    Time frame: Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle

  4. Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Any AE

    AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

    Time frame: Days 1 to 31 (discharge), continuously

  5. Number of Participants With Marked Abnormalities in Serum Chemistry Test Results

    LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Safety criteria: AST and ALT: If \>1.25\*ULN, or if preRX\>ULN, use \>1.25\*preRX. Total and direct bilirubin: If \>1.1\*ULN or if preRX\>ULN, use \>1.25\*preRX. Creatinine: If \>1.33\*preRX. Serum glucose, fasting: If preRX\<LLN, use \<.8\*preRX or \>ULN; if preRX\>ULN, use \>2\*preRX or \<LLN. Creatinine kinase: If \>1.5\*ULN or preRX\>ULN, use \>1.5\*or preRX. Lactose dehydrogenase: If \>1.25\*ULN or preRX\>ULN, use \>1.5\*preRX.

    Time frame: Within 21 days of Day 1 and on Days 3, 10, 20, 26, and 31 (at discharge)

  6. Number of Participants With Marked Abnormalities in Hematology Laboratory Test and Urinalysis Results

    LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Safety criteria: Neutrophils + bands: If \<.85\*LLN or \>1.15\*ULN or ULN or if preRX\<LLN, use \<0.85\*preRX or \>ULN; if preRX\>ULN, use \>1.15\*preRX or \<LLN. Lymphocytes, relative: If \<0.85\*LLN or \>1.15\*ULN, or if preRX \<LLN, use \<0.85\*preRX or \>ULN; if preRX \>ULN, use \>1.15\*preRX or \<LLN. Blood, urine: If \>= 2+, or if preRX \>=1+, use \>=2\*preRX. White blood cells, urine: If \>=2+, or if preRX \>=2+, use \>=4+. Red blood cells, urine: If \>=2+ or if preRX \>=2+, use \>=4+. Not all categories were evaluated for each arm.

    Time frame: Within 21 days of Day 1 and on Days 3, 10, 20, 26, and 31 (at discharge)

  7. Number of Participants With Investigator-identified Abnormalities in Electrocardiogram Results Not Present Prior to Administration of Study Drug and Considered Not Relevant and Not AEs by Investigator

    volt=voltage; LVH=left ventricular hypertrophy

    Time frame: Within 21 days of Day 1 and on Days -1, 21, and 31 (at discharge)

  8. Number of Participants With Abnormalities in Vital Signs

    Time frame: Within 21 days of Day 1 and on Days -1, 1, 3, 11, 21, and 31 (at discharge)

08

Results

Posted Oct 25, 2012

Participant flow

Days 1-3
Participant flow — Days 1-3
MilestoneVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)Atazanavir/Ritonavir, 300/100 QD (PM)
Started2400800
Completed2400800
Not completed000000
Days 11-20
Participant flow — Days 11-20
MilestoneVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)Atazanavir/Ritonavir, 300/100 QD (PM)
Started0240008
Completed0210008
Not completed030000
Withdrew: Adverse event020000
Withdrew: Withdrawal by subject010000
Days 21-30
Participant flow — Days 21-30
MilestoneVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)Atazanavir/Ritonavir, 300/100 QD (PM)
Started0021080
Completed0020070
Not completed001010
Withdrew: Adverse event001000
Withdrew: Withdrawal by subject000010

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in Participants Who Are Extensive Metabolizers (EM)

EM participants are those with functional CYP2C19 alleles.

Time frame:
Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax) and Minimum Observed Plasma Concentration (Cmin) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in Participants Who Are Extensive Metabolizers (EM)
ng/mLAtazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)
Atazanavir Cmin674 ± 61525 ± 50
Atazanavir Cmax4715 ± 274076 ± 23
PrimaryTime to Maximum Concentration (Tmax) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

Time frame:
Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Reported as:
Median · Hours
Time to Maximum Concentration (Tmax) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
HoursAtazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)
Time to Maximum Concentration (Tmax) of Atazanavir, Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants3.0 (2.0 to 4.0)2.07 (2.0 to 4.0)
PrimaryArea Under the Plasma Concentration-time Curve in 1 Dosing Interval [AUC(TAU)] of Atazanavir Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

Time frame:
Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Reported as:
Geometric mean · ng*h/mL
Area Under the Plasma Concentration-time Curve in 1 Dosing Interval [AUC(TAU)] of Atazanavir Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
ng*h/mLAtazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)
Area Under the Plasma Concentration-time Curve in 1 Dosing Interval [AUC(TAU)] of Atazanavir Administered as Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants44634 ± 3538276 ± 28
SecondaryCmax and Cmin of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

Cmax=maximum observed plasma concentration; Cmin=minimum observed plasma concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

Time frame:
Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Reported as:
Geometric mean · ng/mL
Cmax and Cmin of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
ng/mLAtazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)
Ritonavir Cmax1597 ± 401429 ± 38
Ritonavir Cmin37.1 ± 6128.3 ± 69
SecondaryTmax of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

Tmax=time to maximum concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

Time frame:
Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Reported as:
Median · Hours
Tmax of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
HoursAtazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)
Tmax of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants4.0 (1.5 to 5.0)4.0 (2.0 to 4.0)
PrimaryTmax of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants

Tmax=time to maximum concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle
Reported as:
Median · Hours
Tmax of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants
HoursVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)
Tmax of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants1.50 (0.5 to 3.0)1.25 (1.0 to 3.0)
PrimaryCmax and Cmin of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants

Cmax=maximum observed plasma concentration; Cmin=minimum observed plasma concentration; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle
Reported as:
Geometric mean · ng/mL
Cmax and Cmin of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants
ng/mLVoriconazole, 200 BIDAtazanavir/Ritonavir, 300/100mg QD + Voriconazole, 200 mg BID
Voriconazole Cmax3416 ± 493014 ± 47
Voriconazole Cmin776 ± 92439 ± 144
PrimaryAUC(TAU)of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants

AUC(TAU)=area under the plasma concentration-time curve in 1 dosing interval; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

Time frame:
Predose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 12 hours postdoseDays 3 and 30 of a 30-day cycle
Reported as:
Geometric mean · ng.h/mL
AUC(TAU)of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants
ng.h/mLVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)
AUC(TAU)of Voriconazole, Administered With and Without Atazanavir/Ritonavir, in EM Participants20284 ± 6512944 ± 89
SecondaryAUC(TAU) of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants

AUC(TAU)=area under the plasma concentration-time curve in 1 dosing interval; EM=extensive metabolizers, or participants with functional CYP2C19 alleles.

Time frame:
Predose and at 1, 2, 3, 4, 5, 7, 9,13, and 24 hours postdose on Days 20 and 30 of a 30-day cycle
Reported as:
Geometric mean · ng.h/mL
AUC(TAU) of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants
ng.h/mLAtazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)
AUC(TAU) of Ritonavir, Administered As Atazanavir/Ritonavir With and Without Voriconazole, in EM Participants9572 ± 378280 ± 32
SecondaryNumber of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Any AE

AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.

Time frame:
Days 1 to 31 (discharge), continuously
Reported as:
Number · Participants
Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Any AE
ParticipantsVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)Atazanavir/Ritonavir, 300/100 QD (PM)
Deaths000000
SAEs000000
AEs leading to discontinuation021000
Any AE222421032
SecondaryNumber of Participants With Marked Abnormalities in Serum Chemistry Test Results

LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Safety criteria: AST and ALT: If \>1.25\*ULN, or if preRX\>ULN, use \>1.25\*preRX. Total and direct bilirubin: If \>1.1\*ULN or if preRX\>ULN, use \>1.25\*preRX. Creatinine: If \>1.33\*preRX. Serum glucose, fasting: If preRX\<LLN, use \<.8\*preRX or \>ULN; if preRX\>ULN, use \>2\*preRX or \<LLN. Creatinine kinase: If \>1.5\*ULN or preRX\>ULN, use \>1.5\*or preRX. Lactose dehydrogenase: If \>1.25\*ULN or preRX\>ULN, use \>1.5\*preRX.

Time frame:
Within 21 days of Day 1 and on Days 3, 10, 20, 26, and 31 (at discharge)
Reported as:
Number · Participants
Number of Participants With Marked Abnormalities in Serum Chemistry Test Results
ParticipantsVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atazanavir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)Atazanavir/Ritonavir, 300/100 QD (PM)
Aspartate aminotransferase (AST) (U/L): High001000
Alanine aminotransferase (ALT) (U/L): High011011
Total bilirubin (mg/dL): High42221087
Direct bilirubin (mg/dL): High000022
Creatinine (mg/dL): High000001
Serum glucose, fasting (mg/dL): Low100000
Creatine kinase (U/L): High013000
Lactase dehydrogenase (U/L): High110000
SecondaryNumber of Participants With Marked Abnormalities in Hematology Laboratory Test and Urinalysis Results

LLN=lower limit of normal; ULN=upper limit of normal; preRX=pretreatment. Safety criteria: Neutrophils + bands: If \<.85\*LLN or \>1.15\*ULN or ULN or if preRX\<LLN, use \<0.85\*preRX or \>ULN; if preRX\>ULN, use \>1.15\*preRX or \<LLN. Lymphocytes, relative: If \<0.85\*LLN or \>1.15\*ULN, or if preRX \<LLN, use \<0.85\*preRX or \>ULN; if preRX \>ULN, use \>1.15\*preRX or \<LLN. Blood, urine: If \>= 2+, or if preRX \>=1+, use \>=2\*preRX. White blood cells, urine: If \>=2+, or if preRX \>=2+, use \>=4+. Red blood cells, urine: If \>=2+ or if preRX \>=2+, use \>=4+. Not all categories were evaluated for each arm.

Time frame:
Within 21 days of Day 1 and on Days 3, 10, 20, 26, and 31 (at discharge)
Reported as:
Number · Participants
Number of Participants With Marked Abnormalities in Hematology Laboratory Test and Urinalysis Results
ParticipantsVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)Atazanavir/Ritonavir, 300/100 QD (PM)
Neutrophils + bands(absolute)(*10^3 cells/uL): Low101000
Lymphocytes, relative (*10*3 cells/uL): Low111NANANA
Lymphocytes, relative (*10*3 cells/uL): High511NANANA
Blood, urine: High112000
White blood cells (WBC), urine: High10NANANANA
Red blood cells (RBC), urine: High10NANANANA
SecondaryNumber of Participants With Investigator-identified Abnormalities in Electrocardiogram Results Not Present Prior to Administration of Study Drug and Considered Not Relevant and Not AEs by Investigator

volt=voltage; LVH=left ventricular hypertrophy

Time frame:
Within 21 days of Day 1 and on Days -1, 21, and 31 (at discharge)
Reported as:
Number · Participants
Number of Participants With Investigator-identified Abnormalities in Electrocardiogram Results Not Present Prior to Administration of Study Drug and Considered Not Relevant and Not AEs by Investigator
ParticipantsVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)Atazanavir/Ritonavir, 300/100 QD (PM)
Sinus bradycardia000020
ST elevation and fusion complexes000010
T-wave abnormality + minimum volt criteria for LVH000010
Nonspecific T-wave abnormality000010
SecondaryNumber of Participants With Abnormalities in Vital Signs
Time frame:
Within 21 days of Day 1 and on Days -1, 1, 3, 11, 21, and 31 (at discharge)
Reported as:
Number · Participants
Number of Participants With Abnormalities in Vital Signs
ParticipantsVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atanazivir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)Atazanavir/Ritonavir, 300/100 QD (PM)
Diastolic blood pressure000000
Systolic blood pressure000000
Heart rate000000
Respiratory rate000000
Temperature000000

Adverse events

Collected over Days 1 through 30, continuously, of a 30-day cycle.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Voriconazole, 200 BID (EM)—0/24 (0%)22/24 (91.7%)
Atazanavir/Ritonavir, 300/100 QD (EM)—0/24 (0%)24/24 (100%)
Atazanavir/Ritonavir, 300/100 QD (PM)—0/8 (0%)2/8 (25%)
Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)—0/21 (0%)17/21 (81%)
Voriconazole, 50 mg BID (PM)—0/8 (0%)0/8 (0%)
Atazanazvir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)—0/8 (0%)3/8 (37.5%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventVoriconazole, 200 BID (EM)Atazanavir/Ritonavir, 300/100 QD (EM)Atazanavir/Ritonavir, 300/100 QD (PM)Atazanavir/Ritonavir, 300/100mgQD + Voriconazole, 200mgBID(EM)Voriconazole, 50 mg BID (PM)Atazanazvir/Ritonavir, 300/100 QD + Voriconazole, 50 BID (PM)
HyperbilirubinaemiaHepatobiliary disorders2/2415/240/80/210/80/8
HeadacheNervous system disorders12/243/240/82/210/80/8
PhotophobiaEye disorders10/240/240/84/210/80/8
Ocular icterusEye disorders0/248/240/80/210/80/8
Vision blurredEye disorders8/241/240/85/210/80/8
JaundiceHepatobiliary disorders0/248/240/80/210/80/8
PhotopsiaEye disorders4/240/240/86/210/80/8
Blood bilirubin increasedInvestigations1/246/241/81/210/80/8
DizzinessNervous system disorders6/241/240/83/210/80/8
Visual impairmentEye disorders5/241/240/83/210/80/8

Baseline characteristics

Age Continuous
Age Continuous(years)Extensive Metabolizers (EM)Poor Metabolizers (PM)Total
Mean31 ± 1030 ± 731 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Extensive Metabolizers (EM)Poor Metabolizers (PM)Total
Female404
Male20828
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Extensive Metabolizers (EM)Poor Metabolizers (PM)Total
Asian2810
Black or African American101
White20020
Not reported000
Other101
CYP2C19 Genotype of Participants
CYP2C19 Genotype of Participants(Participants)Extensive Metabolizers (EM)Poor Metabolizers (PM)Total
1/111011
1/2505
1/17606
2/2066
2/3011
2/17101
17/17101
3/3011
09

Study locations

2 sites
  • West Coast Clinical Trials, Llc
    Cypress, California 90630, United States
  • Local Institution
    Nijmegen, 6425 GA, Netherlands
10

References and documents

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2009, a primary completion of Jul 2010 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2012, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2009
First posted
Feb 2, 2009
Start
Sep 2009
Primary completionActual
Jul 2010
CompletionActual
Feb 2011
Results first posted
Oct 25, 2012
Last update
Oct 25, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 25, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00833482
Responsible party
Sponsor
First posted
Feb 2, 2009
Start date
Sep 2009
Primary completion
Jul 2010
Completion
Feb 2011
Results posted
Oct 25, 2012
Last update
Oct 25, 2012

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Voriconazole · Atazanavir · Ritonavir

Start the discussion